New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index
Standard
New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index. / Terracciano, Daniela; La Civita, Evelina; Athanasiou, Alcibiade; Liotti, Antonietta; Fiorenza, Mariano; Cennamo, Michele; Crocetto, Felice; Tennstedt, Pierre; Schiess, Ralph; Haese, Alexander; Ferro, Matteo; Steuber, Thomas.
in: PROSTATE, Jahrgang 82, Nr. 15, 11.2022, S. 1469-1476.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index
AU - Terracciano, Daniela
AU - La Civita, Evelina
AU - Athanasiou, Alcibiade
AU - Liotti, Antonietta
AU - Fiorenza, Mariano
AU - Cennamo, Michele
AU - Crocetto, Felice
AU - Tennstedt, Pierre
AU - Schiess, Ralph
AU - Haese, Alexander
AU - Ferro, Matteo
AU - Steuber, Thomas
N1 - © 2022 Wiley Periodicals LLC.
PY - 2022/11
Y1 - 2022/11
N2 - OBJECTIVES: Prostate health index (PHI) and, more recently, Proclarix have been proposed as serum biomarkers for prostate cancer (PCa). In this study, we aimed to evaluate Proclarix and PHI for predicting clinically significant prostate cancer (csPCa).PATIENTS AND METHODS: Proclarix and PHI were measured using samples of 344 men from two different centers. All patients underwent prostate biopsy, and among those, 188 men with PCa on biopsy had an additional radical prostatectomy (RP). All men had a prostate-specific antigen (PSA) between 2 and 10 ng/ml. Evaluation of area under the curve (AUC) and performance at predefined cut-offs of Proclarix and PHI risk scores as well as the linear combination thereof was performed to predict csPCa. PSA density was used as an independent comparator.RESULTS: The cohort median age and PSA were 65 (interquartile range [IQR]: 60-71) and 5.6 (IQR: 4.3-7.2) ng/ml, respectively. CsPCa was diagnosed in 161 (47%) men based on the RP specimen. ROC analysis showed that Proclarix and PHI accurately predicted csPCa with no significant difference (AUC of 0.79 and 0.76, p = 0.378) but significantly better when compared to PSA density (AUC of 0.66, p < 0.001). When using specific cut-offs, Proclarix (cut-off 10) revealed higher specificity and positive predictive value than PHI (cut-off 27) at similar sensitivities. The combination of Proclarix and PHI provided a significant increase in the AUC (p ≤ 0.007) compared to the individual tests alone and the highest clinical benefit was achieved.CONCLUSION: Results of this study show that both Proclarix and PHI accurately detect the presence of csPCa. The model combining Proclarix and PHI revealed the synergistic effect and improved the diagnostic performance of the individual tests.
AB - OBJECTIVES: Prostate health index (PHI) and, more recently, Proclarix have been proposed as serum biomarkers for prostate cancer (PCa). In this study, we aimed to evaluate Proclarix and PHI for predicting clinically significant prostate cancer (csPCa).PATIENTS AND METHODS: Proclarix and PHI were measured using samples of 344 men from two different centers. All patients underwent prostate biopsy, and among those, 188 men with PCa on biopsy had an additional radical prostatectomy (RP). All men had a prostate-specific antigen (PSA) between 2 and 10 ng/ml. Evaluation of area under the curve (AUC) and performance at predefined cut-offs of Proclarix and PHI risk scores as well as the linear combination thereof was performed to predict csPCa. PSA density was used as an independent comparator.RESULTS: The cohort median age and PSA were 65 (interquartile range [IQR]: 60-71) and 5.6 (IQR: 4.3-7.2) ng/ml, respectively. CsPCa was diagnosed in 161 (47%) men based on the RP specimen. ROC analysis showed that Proclarix and PHI accurately predicted csPCa with no significant difference (AUC of 0.79 and 0.76, p = 0.378) but significantly better when compared to PSA density (AUC of 0.66, p < 0.001). When using specific cut-offs, Proclarix (cut-off 10) revealed higher specificity and positive predictive value than PHI (cut-off 27) at similar sensitivities. The combination of Proclarix and PHI provided a significant increase in the AUC (p ≤ 0.007) compared to the individual tests alone and the highest clinical benefit was achieved.CONCLUSION: Results of this study show that both Proclarix and PHI accurately detect the presence of csPCa. The model combining Proclarix and PHI revealed the synergistic effect and improved the diagnostic performance of the individual tests.
KW - Humans
KW - Male
KW - Prospective Studies
KW - Prostate/pathology
KW - Prostate-Specific Antigen
KW - Prostatectomy
KW - Prostatic Neoplasms/diagnosis
U2 - 10.1002/pros.24422
DO - 10.1002/pros.24422
M3 - SCORING: Journal article
C2 - 35971798
VL - 82
SP - 1469
EP - 1476
JO - PROSTATE
JF - PROSTATE
SN - 0270-4137
IS - 15
ER -